CRBP — Corbus Pharmaceuticals Holding

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Corbus Pharmaceuticals Holding

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$7.91
Market Cap$228M
Float12.7M
Shares Outstanding18.5M
Price/Sales (TTM)169.88
vs. Analyst Target+385.5% to analyst PT
Dividend RateNone
Analyst Target Price$38.40 (10 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $3.9M -$111M $3.9M -$121M
2021 $881,705 -$45.6M -$757,527 -$54.3M
2022 N/A -$55.8M -$1.5M -$38.7M
2023 N/A -$44.6M -$31.2M -$40.1M
2024 N/A -$40.2M -$600,000 -$37.7M
2025 N/A -$78.5M -$233,000 -$78.3M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 N/A -$17.7M
Sep 2025 N/A -$23.3M
Dec 2025 N/A -$20.6M
Mar 2026 N/A -$23.0M

Ownership & Float

Insider Ownership0.6%
Institutional Ownership71.9%
Short Float11.0%
% of All Funds Holding1.17%
Number of Funds Holding96

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$10.09Near-term / short-term trend
Weekly40-Week SMA$10.31Medium-term trend
Weekly80-Week SMA$9.82Cyclical trend (business cycle)
Weekly200-Week SMA$14.54Secular trend (multi-year)
Monthly10-Month SMA$9.79Near-term monthly trend
Monthly20-Month SMA$9.86Medium-term monthly trend
Monthly40-Month SMA$15.90Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$9.90 resistance 1.50x 0 months ago
$11.40 resistance 1.95x 4 months ago
$60.00 resistance 2.26x 19 months ago

Historical Earnings Reactions (46 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 1.46% 1.07% 65.22% 10.37% -3.31%
1 Day 1.14% 0.98% 54.35% 20.14% -9.05%
1 Week 3.82% 3.45% 60.87% 27.91% -16.51%
2 Weeks 11.75% 5.19% 66.67% 150.38% -20.21%
1 Month 12.50% 3.68% 60.00% 198.12% -61.45%

Next earnings: July 31, 2026 (65 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan30.8%58.3%12
Feb-2.9%41.7%12
Mar19.2%66.7%12
Apr5.3%58.3%12
May7.9%63.6%11
Jun-6.5%27.3%11
Jul-5.0%27.3%11
Aug9.6%63.6%11
Sep-8.7%27.3%11
Oct-12.4%18.2%11
Nov12.0%66.7%12
Dec-12.1%25.0%12

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.11% 45.2% 544
Tuesday -0.29% 42.5% 600
Wednesday 0.30% 46.2% 597
Thursday 0.62% 48.3% 584
Friday 0.20% 42.8% 584

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 71.9%

Insider Transactions — Smart Summary

Total insider ownership: 0.6%

Founder-led management: Yuval Cohen (Chief Executive Officer & Director)

12-Month Insider Activity Summary

Total Filings12
Net Value-$766,631.695
Net Shares Change-55,820
% of Float-0.4%
C-Suite Filings8
Clusters Detected2

Key Insiders

NameTitleNet ValueFilingsActivity
Cormorant Asset Management, LP -$344,012.224 1 1 sell
Moran Sean F. Chief Financial Officer -$202,225.443 2 N/A
Cohen Yuval Chief Executive Officer -$107,952.445 1 N/A
Smethurst Dominic Chief Medical Officer -$77,176.435 2 N/A
Hodgson Ian Chief Operating Officer -$25,790.51 2 N/A
Jenkins John Kenneth -$20,465.347 1 N/A
Altmeyer Anne -$10,095.619 1 N/A

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2025-10-21 – 2025-10-27 3 3 -$535,766.423 2 C-suite
2026-02-04 – 2026-02-18 5 4 -$196,905.83 5 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2025-12-15 Cormorant Asset Management, LP -$344,012.224 Transaction at $11.46, now -31.0%
2026-03-04 Smethurst Dominic Chief Medical Officer -$50,601.442 Transaction at $8.30, now -4.7%
2026-02-18 Cohen Yuval Chief Executive Officer -$107,952.445 Transaction at $7.78, now +1.6%
2025-06-02 Jenkins John Kenneth -$20,465.347 Transaction at $7.35, now +7.6%
2025-06-02 Altmeyer Anne -$10,095.619 Transaction at $7.25, now +9.1%
2026-02-18 Moran Sean F. Chief Financial Officer -$36,587.883 Transaction at $7.78, now +1.6%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Corbus Pharmaceuticals Holding (CRBP) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CRBP on Trend Edge →